SavedAdd your journal

Journals / Cumhuriyet Science Journal / 2022 / Cilt: 43 - Sayı: 2

Quantum Chemical Benchmark Study on Valdecoxib, a Potent and Selective Inhibitor of COX-2, and its Hydroxylated Derivative

Sümeyya SERİN
Öznur DOĞAN ULU
Pages
221–231
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Molecular lipophilicity potential (MLP)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this work, quantum chemical calculations were performed on valdecoxib (VLB), a highly selective and potent COX-2 inhibitor, and its hydroxylated derivative (1H-VLB), an active metabolite.
📊
Key Findings & Data:The geometry optimizations and frequency calculations were carried out by using density functional theory (DFT)/B3LYP functional with the 6- 311++G (d, p) basis set.
💡
Conclusion & Impact:Molecular lipophilicity potential (MLP)
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this work, quantum chemical calculations were performed on valdecoxib (VLB), a highly selective and potent COX-2 inhibitor, and its hydroxylated derivative (1H-VLB), an active metabolite. The geometry optimizations and frequency calculations were carried out by using density functional theory (DFT)/B3LYP functional with the 6- 311++G (d, p) basis set. To define water phase behaviors, calculations were renewed by using universal SMD solvation model for both molecules. Structural and thermodynamic parameters, FT-IR analysis, Mulliken population analysis (MPA), frontier molecular orbital (FMO) analysis, natural bond orbital (NBO) analysis, and electrostatic surface properties were investigated in detail. Quantum chemical reactivity identifiers were calculated separately for both vacuum and water environment in order to evaluate the bioactivity tendency of both mentioned compounds. When the bioactivity of VLB and 1H-VLB molecules were compared based on quantum chemical reactivity identifiers, it was observed that the VLB molecule was more active. Moreover, druglikeness properties of studied molecules were predicted by means of Molinspiration cheminformatics software. Molecular lipophilicity potential (MLP)

🔖

Cite This Article

SERİN, S., ULU, Ö. D. (2022). Quantum Chemical Benchmark Study on Valdecoxib, a Potent and Selective Inhibitor of COX-2, and its Hydroxylated Derivative. Cumhuriyet Science Journal, Cilt: 43 - Sayı: 2, 221–231. https://ajindex.com/articles/477455

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Vane J.R., Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs, Nature New Biol., 231 (1971) 232–235
  2. Fu J. R., Masferrer J. L., Seibert K., Raz A., Needle-man P., The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes, J. Biol. Chem., 265 (1990) 265 16737-16740
  3. Battistini B., Botting B., Bakhle Y., SCOX-1 and COX-2:Toward the development of more selective NSAİDs, Drug News Perspect., 7 (1994) 501
  4. Sayed G., Abou-seri S.M., Kamel G., Moawad M., Celecoxib analogs bearing ben- zofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evalua- tion as potential anti-inflammatory agents, Eur. J. Med. Chem., 76 (2014) 482–493
  5. Abdelall E.K.A., Lamie P.F., Ahmed A.K.M., El-nahass E., COX-1/COX- 2 inhibi- tion assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core, Bioorg. Chem., 86 (2019) 235–253
  6. Raz A., Wyche A., Siegel N., Needleman P., Regulation of fibroblast cyclooxygenase synthesis by interleukin-1, J. Biol.Chem., 263 (1988) 263 3022-3028
  7. Wang C., Chen F., Qian P., Cheng J., Recent advances in the Rhcatalyzed cascade arene C–H bond activation/annulation toward diverse heterocyclic compounds, Org. Biomol. Chem., 19 (2021) 1705-1721
  8. Mermer A., Keleş T., Şirin Y., Recent studies of nitrogen containing heterocyclic compounds as novelantiviral agents: A review, Bioorg. Chem., 114 (2021) 105076
  9. Zhu Jun J., Hong-zhi M., Yao L., Chen Y., Sun H., The recent progress of isoxazole in medicinal chemistry, Bioorg. Med. Chem., 26 (2018) 3065–3075
  10. Scheen A.J., Malaise M., Le medicament du mois.Valdecoxib (Bextra), Rev. Med. Liege, 59 (2004) 251-254
  11. Erdelyi P., Fodor t., Varga A.K., Czugler M., Gere A., Fischer J., Chemical and biological investigation of N-hydroxy-valdecoxib:An active metabolite of valdecoxib, Bioorg. Med. Chem., 16 (2008) 5322–5330
  12. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.SShaffer A.F., Zhang Y.Y., Zweifel B.S., Seibert K., 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A potent and selective Inhibitor of COX-2, J. Med. Chem., 43 (2000), 775-777
  13. Van De Waterbeemd H., Gifford E., ADMET in silico modelling: towards prediction paradise?, Nat. Rev. Drug Discov., 3 (2003) 192- 204
  14. Borges R. M., Colby S. M., Das S., Edison A. S., Fiehn O., Kind T., Lee J., Merrill A. T